Thailand and Indonesia unveil plans to develop molnupiravir Covid-19 pill
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BANGKOK] Thailand's health minister said on Friday the country planned to develop the anti-viral pill molnupiravir to combat Covid-19 infections amid rising infections driven by the Omicron variant.
The molnupiravir Covid-19 treatment pill for adult patients at risk of developing severe illness was jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics.
The Southeast Asian nation intends to join other countries in the region also planning to make versions of the drug including Bangladesh and India.
"For molnupiravir, the Government Pharmaceutical Organization has plans to co-develop (this drug) with the Chulabhorn Research Institute," Minister Anutin Charnvirakul told a news conference.
"A committee will research and produce the reactants, which will be additional support for future events," he said.
Separately, Indonesia's health minister Budi Gunadi Sadikin said on Friday the country also planned to develop molnupiravir in partnership with pharmaceutical company PT Amarox Pharma Global starting in April or May.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Indonesia approved molnupiravir for emergency use this week and 400,000 pills have arrived.
Thailand has ordered 50,000 courses of molnupiravir from Merck and was still in discussion with Pfizer for 50,000 courses of its drug Paxlovid.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts